In a generally healthy adult without cardiac disease, electrolyte abnormalities, or a history of movement disorders, which pro‑kinetic tablet—domperidone, metoclopramide, itopride, cisapride, or levosulpiride—is safest?

Metoclopramide is the safest first-line prokinetic agent among those listed for a generally healthy adult

Based on the most recent 2025 AGA guidelines, metoclopramide is the only prokinetic agent with a conditional recommendation FOR use, while domperidone is explicitly recommended AGAINST as first-line therapy 1. The other agents you mention (itopride, cisapride, levosulpiride) lack guideline support and have significant safety concerns.

Safety Profile Comparison

Metoclopramide (Recommended First-Line)

• FDA-approved with established safety monitoring protocols 2
• Black box warning for tardive dyskinesia (TD), but absolute risk is LOW even in higher-risk populations 1
• Acute dystonic reactions occur in ~1 in 500 patients, primarily in those <30 years old, and are reversible with diphenhydramine 2
• Risk mitigation strategies are well-established: start 5 mg before meals, use drug holidays (1-4 weeks off every 8-12 weeks), limit duration to 12 weeks when possible 1
• Depression risk exists but is manageable with appropriate patient selection 2

Domperidone (NOT Recommended First-Line)

• AGA explicitly recommends AGAINST first-line use (conditional recommendation, very low quality evidence) 1
• Not FDA-approved in the United States; requires investigational new drug application 1
• QT prolongation and ventricular arrhythmias are primary concerns 3, 4
• Requires baseline ECG, potassium, and magnesium monitoring before initiation 1
• Research shows domperidone blocks cardiac Na+ channels potently (IC50 85 μM for Nav1.5), contributing to cardiotoxicity 5
• May be considered as second-line if metoclopramide causes neurologic side effects 1

Cisapride (AVOID)

• Withdrawn from most markets due to severe cardiac toxicity 6
• Causes QT prolongation and life-threatening ventricular arrhythmias 6
• Multiple dangerous drug interactions via CYP3A4 inhibition 6
• Should not be used given availability of safer alternatives

Itopride

• No guideline recommendations; limited high-quality evidence
• One comparative study showed similar efficacy to domperidone for dyspepsia 7
• Paradoxically, a 2020 population study found itopride had higher risk of severe ventricular arrhythmia compared to domperidone (adjusted IRR 1.486 vs 1.342) 3
• Lacks the established safety monitoring protocols of metoclopramide

Levosulpiride

• No guideline support or FDA approval in most Western countries
• Associated with movement disorders similar to metoclopramide 8
• Insufficient safety data compared to metoclopramide

Clinical Decision Algorithm

For a healthy adult without cardiac disease, electrolyte abnormalities, or movement disorders:

1. Start with metoclopramide 5 mg orally before meals (can increase to 10 mg) 1

   • Counsel patient on low but real risk of movement disorders
   • Plan 4-8 week assessment for efficacy and adverse effects
   • Implement drug holidays if long-term use needed

2. If metoclopramide causes neurologic side effects:

   • Consider domperidone (if available) with mandatory ECG and electrolyte monitoring 1
   • Check baseline potassium, magnesium, and QTc interval before starting

3. Avoid cisapride entirely due to cardiac toxicity

4. Do not use itopride or levosulpiride as first-line given lack of guideline support and unclear safety advantage

Key Safety Caveats

• Metoclopramide's tardive dyskinesia risk increases with duration and cumulative dose 2, but the 2025 AGA guidelines emphasize the absolute risk remains low even in elderly, women, and diabetics 1
• All prokinetics carry some cardiac risk: Even metoclopramide can cause QT prolongation, though less than domperidone 5
• Drug holidays are critical for maintaining efficacy and potentially reducing adverse effects with metoclopramide 1
• Avoid treatment >12 weeks unless therapeutic benefit clearly outweighs TD risk 2

The evidence strongly supports metoclopramide as the safest option with the most robust safety monitoring framework, despite its FDA black box warning. The warning reflects appropriate caution for a real but uncommon risk, not a contraindication to use in appropriate patients with proper monitoring.